SD BIOSENSOR reported on the 18th that its consolidated operating loss last year was 54.1 billion won, a decrease of 78.2% compared to the previous year. During the same period, the net loss was also 98.1 billion won, down 79% from the previous year.
Last year's revenue increased by 5.9% to 694.6 billion won compared to the previous year. The company noted that the operating loss was due to amortization expenses related to intangible assets arising from the consolidation accounting process of U.S. Meridian Bioscience, and emphasized that it was an accounting expense without cash outflow. On a separate basis, the operating profit was 4.7 billion won and the net profit was 6.3 billion won, marking improvements of 103% and 102%, respectively, compared to the previous year, successfully returning to profit.
According to SD BIOSENSOR, revenue improved as sales of non-COVID-19 products expanded, with sales in the Americas, Africa, and Asia regions rising compared to the previous year. By disease, blood sugar diagnosis products, sexually transmitted disease diagnosis products including simultaneous diagnosis kits for human immunodeficiency virus (HIV) and syphilis, respiratory disease products including simultaneous diagnosis kits for COVID-19 and influenza, and malaria diagnosis kits for vector-borne infections recorded high sales in that order.
In particular, sales of Meridian and other subsidiaries surged last year, driving the company's global growth. The Brazilian subsidiary saw a 90% increase in sales compared to the previous year, thanks to government contracts for HIV and hepatitis C diagnosis kits and expanded supply of COVID-19 and dengue virus diagnostic products. Subsidiaries in Italy, Indonesia, and Panama also reported operating profits. The Indian subsidiary increased sales based on hemoglobin A1c (HbA1c) and malaria diagnostic products.
SD BIOSENSOR is broadening its product range through continued investment in research and development for its existing rapid immune diagnosis Standard Q (STANDARD Q), fluorescent immune diagnosis Standard F (STANDARD F), molecular diagnosis Standard M (STANDARD M), and chronic care brands. The company is also preparing to launch a continuous glucose monitoring system (CGMS) product to strengthen its diagnostic platform competitiveness.
A company official said, "We plan to maximize cost competitiveness and increase annual production capacity by more than 2.9 times through the state-of-the-art automated equipment at the new factory in India, which was completed last February, and further strengthen our position in the global market."